ReviewBlood2016
How I treat acute myeloid leukemia presenting with preexisting comorbidities.
Review in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Article
- Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant and NMDP Donor Search in Older Adults with Acute Myeloid Leukemia.Transplantation and cellular therapy · 2026Article
- Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant-Eligible and Ineligible Acute Myeloid Leukemia.Cancer medicine · 2026Article
- Case Report: FIA plus venetoclax in a patient on hemodialysis.Frontiers in oncology · 2025Article
- AML in the Elderly - When less may be more.Current oncology reports · 2024Review
- Acute myeloid leukemia presenting with hepatic dysfunction: Should induction be dose reduced?EJHaem · 2024Article
- Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications.European journal of medical research · 2024Review
- Approach to the Older Patient with Acute Myeloid Leukemia.Current oncology reports · 2023Review
- Article
- Intravoxel incoherent motion diffusion-weighted MRI of renal parenchyma and its clinical significance in patients with untreated acute leukemia: a pilot study.Abdominal radiology (New York) · 2023Article
- Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.Annals of hematology · 2023Article
- Acute kidney injury and childhood acute myeloid leukemia.Pediatric nephrology (Berlin, Germany) · 2022Article
- Article
- Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.PloS one · 2022Article
- Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice.Leukemia research reports · 2021Article
- Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.Blood advances · 2020Review
- Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulatingAmerican journal of translational research · 2020Article
- Methylation-independentAmerican journal of translational research · 2020Review
- Anti-leukemic effects of simvastatin on NRASMolecular biology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Acute myeloid leukemia (AML) is a devastating disease with an incidence that progressively increases with advancing age. Currently, only ∼40% of younger and 10% of older adults are long-term survivors. If untreated, the overall prognosis of AML remains dismal. Initiation of therapy at diagnosis is usually urgent. Barriers to successful therapy for AML are the attendant toxicities directly related to chemotherapy or those associated with inevitable aplasia. Organ dysfunction often further complicates such toxicities and may even be prohibitive. There are few guidelines to manage such patients and the fear of crossing the medico-legal abyss may dominate. Such clinical scenarios provide particular challenges and require experience for optimal management. Herein, we discuss select examples of common pretreatment comorbidities, including cardiomyopathy, ischemic heart disease; chronic renal failure, with and without dialysis; hepatitis and cirrhosis; chronic pulmonary insufficiency; and cerebral vascular disease. These comorbidities usually render patients ineligible for clinical trials and enormous uncertainty regarding management reigns, often to the point of withholding definitive therapy. The scenarios described herein emphasize that with appropriate subspecialty support, many AML patients with comorbidities can undergo therapy with curative intent and achieve successful long-term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.